Total-liver-volume perfusion CT using 3-D image fusion to improve detection and characterization of liver metastases

The aim of this study was to assess and compare fat content within the liver for normal (body mass index (BMI) < 25 kg/m2), overweight (25-30 kg/m2) and obese (≥ 30 kg/m2) subjects using a noninvasive, non-contrast computed tomography (CT) quantification method. Adult subjects aged 18-60 yrs scheduled to undergo CT examination of the abdominal region were recruited for this study, stratified across BMI categories. Liver volume, fat content, and lean liver volume were determined using CT methods. A total of 100 subjects were recruited, including 30 normal weight, 31 overweight, and 39 obese. Total liver volume increased with BMI, with mean values of 1138 ± 277, 1374 ± 331, and 1766 ± 389 cm3 for the normal, overweight, and obese, respectively (P < 0.001), which was due to an increase in both liver fat content and lean liver volume with BMI. Some obese subjects had no or minimal hepatic fat content. The prevalence of mild fatty liver in this study of 100 subjects was overestimated for all BMI categories using a range of qualitative diagnostic measures, with predicted prevalence of fatty liver in obese subjects ranging from 76.9% for liver-to-spleen ratio ≤ 1.1 to 89.7% for liver attenuation index (liver HU - spleen HU) ≤ 40, compared to 66.7% by quantification of fat content. Results show that total liver volume increases with BMI, however, not all obese subjects display fatty infiltration of the liver. CT quantification of liver fat content may be suitable for accurate diagnosis of hepatic steatosis in clinical practice and assessment of donor livers for transplantation.

Download Full-text

Ratio of remnant to total liver volume or remnant to body weight: which one is more predictive on donor outcomes?

HPB ◽

10.1111/j.1477-2574.2012.00483.x ◽

2012 ◽

Vol 14 (7) ◽

pp. 476-482 ◽

Cited By ~ 10

Author(s):

Onur Yaprak ◽

Necdet Guler ◽

Gulum Altaca ◽

Murat Dayangac ◽

Tolga Demirbas ◽

...

Keyword(s):

Body Weight ◽

Liver Volume ◽

Total Liver Volume ◽

Total Liver

Download Full-text

The Correlation between the CT Liver Volume and the Actual Weight of the Resected Cirrhotic Liver in Transplantation Patients

Journal of Health Science and Medical Research ◽

10.31584/jhsmr.2021855 ◽

2021 ◽

Author(s):

Kulyada Eurboonyanun ◽

Chalerm Eurboonyanun ◽

Julaluck Promsorn ◽

Jiranthanin Phaorod ◽

Tharatip Srisuk ◽

...

Keyword(s):

Liver Volume ◽

Future Liver Remnant ◽

P Value ◽

Ct Volumetry ◽

Liver Remnant ◽

Total Liver Volume ◽

Actual Weight ◽

Total Liver ◽

Resected Liver ◽

Functional Liver Volume

Objective: Volumetric assessment with computed tomography (CT), known as CT volumetry, is the preferred method for estimating future liver remnant. However, the data regarding the usage of CT volumetry to estimate future liver remnant of the diseased liver is still lacking. This study was designed to evaluate the correlation between the liver volume, calculated by CT, and the actual weight of the resected liver in patients who underwent orthotopic liver transplantation.Material and Methods: A total of 32 patients having underwent liver transplantation; from March 2009 to June 2015, were included. A radiologist retrospectively reviewed the pre-operative CT and performed the volume measurement. Statistical analysis was performed to determine the relationship between the estimated liver volume and the actual liver weight.Results: The estimated liver volume was significantly different among the cirrhosis of different etiology (p-value=0.001 for the total liver volume and p-value=0.003 for the functional liver volume). Compared with the total liver volume, the functional liver volume had a stronger correlation with the actual weight of the resected liver (r=0.955 vs. r=0.786). The following formula can be used to accurately estimate the expected weight of the resected liver (expected liver weight: ELW), based on the estimated functional liver volume (FLV) derived by CT volumetry: ELW=489.531+(0.618*FLV). The R-squared for this regression model was 0.914.Conclusion: CT volumetry is reliable and accurate in predicting the actual amount of the resected liver parenchyma in cirrhotic patients.

Download Full-text

Is Liver Function Homogenous? Correlation between CT Liver Volumes and Liver Function as Determined by Functional Hepatobiliary (HIDA) Scan

Proceedings of IMPRS ◽

10.18060/22699 ◽

2018 ◽

Vol 1 (1) ◽

Author(s):

Jarrell G. Gary, MS ◽

Paul Haste, MD ◽

Mark Tann, MD

Keyword(s):

Radiation Therapy ◽

Liver Function ◽

Liver Volume ◽

Left Lobe ◽

Liver Remnant ◽

Total Liver Volume ◽

Female Ratio ◽

Total Liver ◽

Hida Scan ◽

The Mean

Background A hepatobiliary (HIDA) scan is a study historically done to evaluate for cholecystitis and more recently shown to be an effective way to measure liver function. Volumetric analysis on computed tomography (CT) is the most common way to evaluate future liver remnant prior to planned partial hepatectomy or radiation therapy. The aim of this study is to determine to what degree do lobar CT volume ratios correlate with distribution of functionality. Experimental Design A retrospective review and analysis of the images for 63 patients with liver cancer, imaged between 2016 and 2018, was performed. All functional HIDA scans were processed using MIM software. Total liver function, with lobar ratios, were obtained. Whole liver and lobar volume analysis on CT was also performed. Results The mean age was 63.6 [Symbol] 11.0 years with a male to female ratio of 1.3:1. The mean total liver volume on CT was 1611.3 [Symbol] 590.5 mL (Right lobe: 961.5 [Symbol] 405.3 mL, Left lobe: 649.8 [Symbol] 331.7 mL). The mean ratio of right to left lobar volumes was 59.5 [Symbol] 13.5 % to 40.6 [Symbol] 13.5%. The mean ratio of right to left lobar liver function was 60.7 [Symbol] 20.7% to 39.5 [Symbol] 21.1%. Conclusion and Potential Impact The overall average ratio between right and left lobe liver function appears to closely relate to the volumetric ratio between the lobes. These promising results suggest that liver function is fairly homogenous, which could provide great value in planning future liver operations and radiation therapy.

Download Full-text

Future liver remnant/total liver volume >30%: hyperbilirubinemia after donor liver resection has mutations of uridine diphosphate glucuronosyltransferase 1 (UGT1A1)

HPB ◽

10.1016/j.hpb.2016.03.526 ◽

2016 ◽

Vol 18 ◽

pp. e572-e573

Author(s):

J. Kaneko ◽

K. Hasegawa ◽

Y. Sakamoto ◽

Y. Maruo ◽

T. Tanaka ◽

...

Keyword(s):

Liver Resection ◽

Liver Volume ◽

Future Liver Remnant ◽

Uridine Diphosphate ◽

Donor Liver ◽

Liver Remnant ◽

Total Liver Volume ◽

Uridine Diphosphate Glucuronosyltransferase ◽

Total Liver

Download Full-text

Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement

Clinical Journal of the American Society of Nephrology ◽

10.2215/cjn.13661119 ◽

2020 ◽

Vol 15 (9) ◽

pp. 1267-1278

Author(s):

Marie C. Hogan ◽

Julie A. Chamberlin ◽

Lisa E. Vaughan ◽

Angela L. Waits ◽

Carly Banks ◽

...

Keyword(s):

Placebo Group ◽

Liver Disease ◽

Liver Volume ◽

Kidney Volume ◽

Polycystic Liver Disease ◽

Total Kidney Volume ◽

Total Liver Volume ◽

Total Liver ◽

Polycystic Liver ◽

Long Acting

Background and objectivesWe assessed safety and efficacy of another somatostatin receptor analog, pasireotide long-acting release, in severe polycystic liver disease and autosomal dominant polycystic kidney disease. Pasireotide long-acting release, with its broader binding profile and higher affinity to known somatostatin receptors, has potential for greater efficacy.Design, setting, participants, & measurementsIndividuals with severe polycystic liver disease were assigned in a 2:1 ratio in a 1-year, double-blind, randomized trial to receive pasireotide long-acting release or placebo. Primary outcome was change in total liver volume; secondary outcomes were change in total kidney volume, eGFR, and quality of life.ResultsOf 48 subjects randomized, 41 completed total liver volume measurements (n=29 pasireotide long-acting release and n=12 placebo). From baseline, there were −99±189 ml/m absolute and −3%±7% change in annualized change in height-adjusted total liver volume (from 2582±1381 to 2479±1317 ml/m) in the pasireotide long-acting release group compared with 136±117 ml/m absolute and 6%±7% increase (from 2387±759 to 2533±770 ml/m) in placebo (P<0.001 for both). Total kidney volumes decreased by −12±34 ml/m and −1%±4% in pasireotide long-acting release compared with 21±21 ml/m and 4%±5% increase in the placebo group (P=0.05 for both). Changes in eGFR were similar between groups. Among the n=48 randomized, adverse events included hyperglycemia (26 of 33 [79%] in pasireotide long-acting release versus four of 15 [27%] in the placebo group; P<0.001), and among the 47 without diabetes at baseline, 19 of 32 (59%) in the pasireotide long-acting release group versus one of 15 (7%) in the placebo group developed diabetes (P=0.001).ConclusionsAnother somatostatin analog, pasireotide long-acting release, slowed progressive increase in both total liver volume/total kidney volume growth rates without affecting GFR decline. Participants experienced higher frequency of adverse events (hyperglycemia and diabetes).Clinical Trial registry name and registration numberPasireotide LAR in Severe Polycystic Liver Disease, NCT01670110PodcastThis article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2020_08_28_CJN13661119.mp3

Download Full-text